Department of Thoracic Oncology, Kansai Medical University Hospital, 2-3-1, Shinmachi, Hirakata City, Osaka, 573-1191, Japan.
Discovery Technology Research, Ono Pharmaceutical, Co., Ltd., Osaka, Japan.
BMC Cancer. 2022 Feb 8;22(1):154. doi: 10.1186/s12885-022-09264-2.
Immune checkpoint inhibitors prolong the survival of non-small cell lung cancer (NSCLC) patients. Although it has been acknowledged that there is some correlation between the efficacy of anti-programmed cell death-1 (PD-1) antibody therapy and immunohistochemical analysis, this technique is not yet considered foolproof for predicting a favorable outcome of PD-1 antibody therapy. We aimed to predict the efficacy of nivolumab based on a comprehensive analysis of RNA expression at the gene level in advanced NSCLC.
This was a retrospective study on patients with NSCLC who were administered nivolumab at the Kansai Medical University Hospital. To identify genes associated with response to anti-PD-1 antibodies, we grouped patients into responders (complete and partial response) and non-responders (stable and progressive disease) to nivolumab therapy. Significant genes were then identified for these groups using Welch's t-test.
Among 42 analyzed cases (20 adenocarcinomas and 22 squamous cell carcinomas), enhanced expression of MAGE-A4, BBC3, and OTOA genes was observed in responders with adenocarcinoma, and enhanced expression of DAB2, HLA-DPB,1 and CDH2 genes was observed in responders with squamous cell carcinoma.
This study predicted the efficacy of nivolumab based on a comprehensive analysis of mRNA expression at the gene level in advanced NSCLC. We also revealed different gene expression patterns as predictors of the effectiveness of anti PD-1 antibody therapy in adenocarcinoma and squamous cell carcinoma.
免疫检查点抑制剂延长了非小细胞肺癌（NSCLC）患者的生存期。虽然已经认识到抗程序性细胞死亡-1（PD-1）抗体治疗的疗效与免疫组织化学分析之间存在一定的相关性，但该技术尚不能完全预测 PD-1 抗体治疗的良好预后。我们旨在通过对晚期 NSCLC 的基因水平 RNA 表达进行综合分析来预测纳武单抗的疗效。
这是一项在关西医科大学医院接受纳武单抗治疗的 NSCLC 患者的回顾性研究。为了确定与抗 PD-1 抗体反应相关的基因，我们将患者分为纳武单抗治疗的应答者（完全和部分缓解）和无应答者（稳定和进展性疾病）。然后使用 Welch's t 检验对这些组进行了显着基因的鉴定。
在分析的 42 例病例中（20 例腺癌和 22 例鳞状细胞癌），观察到腺癌应答者中 MAGE-A4、BBC3 和 OTOA 基因的表达增强，而鳞状细胞癌应答者中 DAB2、HLA-DPB1 和 CDH2 基因的表达增强。
本研究基于晚期 NSCLC 的基因水平 mRNA 表达的综合分析预测了纳武单抗的疗效。我们还揭示了不同的基因表达模式，作为预测抗 PD-1 抗体治疗在腺癌和鳞状细胞癌中的有效性的指标。
